Evidence behind this recommendation.
Selected studies from our library that inform the recommendations on this page. Evidence grade shown when available.
Ankylosing Spondylitis: Inflammatory Axial Spondyloarthritis
Ankylosing spondylitis (AS) is a chronic immune-mediated axial spondyloarthritis, characterized by inflammation of the sacroiliac joints and the spine, with progression to ligament ossification and vertebral fusion (ankylosis). It is one of the most common forms of inflammatory arthritis in young adults — typically beginning between ages 20 and 30 — with a strong association with HLA-B27 (present in 85–90% of cases).
AS has a functional and quality-of-life impact far greater than rheumatoid arthritis in many respects — especially in young, active patients. Nighttime pain, prolonged morning stiffness, and progressive limitation of spinal mobility are the most disabling aspects in daily clinical practice.
Role of Acupuncture in AS
Acupuncture does not modify the radiographic progression of AS, nor does it replace biologic agents (anti-TNF-α, anti-IL-17) when these are indicated. Its role is the control of axial pain, reduction of morning stiffness, and functional improvement as a complement to conventional rheumatologic treatment — especially during periods of inflammatory flare and as an alternative to long-term NSAID use (which carries gastrointestinal and cardiovascular adverse effects).
Conventional Treatment of AS
Treatment of AS follows a progressive escalation based on inflammatory activity, function, and poor prognostic factors — coordinated by the rheumatologist.
THERAPEUTIC ESCALATION IN ANKYLOSING SPONDYLITIS
| LINE | TREATMENT | EFFICACY | LIMITATION |
|---|---|---|---|
| 1st line | NSAIDs at maximum dose (indomethacin, naproxen) | High for pain and stiffness — BASDAI −1.5 pts | GI (gastropathy), cardiovascular, renal; continued use problematic |
| 2nd line (axial) | Anti-TNF-α: adalimumab, etanercept, certolizumab | ASAS40 in 40–60%; reduces MRI inflammation | Immunosuppression, opportunistic infections, high cost |
| 2nd line (axial) | Anti-IL-17: secukinumab, ixekizumab | ASAS40 in 45–65%; better for peripheral manifestations | Candidiasis, IBD — contraindicated in active IBD |
| Complementary | Physical therapy and exercise (ASAS grade A recommendation) | Functional improvement and quality of life | Benefit only with a structured, supervised program |
| Symptomatic | Acetaminophen, weak opioids (flare) | Rescue analgesia | Opioids: tolerance, dependence, worsening of autonomic dysfunction |
Mechanisms of Action in Ankylosing Spondylitis
Acupuncture acts on the pathophysiology of AS through anti-inflammatory and neuromodulatory mechanisms documented in laboratory and clinical studies.
Mechanisms of Action in AS
1. Anti-Inflammatory Modulation — Mechanistic Hypothesis
Experimental studies suggest that electroacupuncture at ST-36 may modulate the HPA axis and inflammatory markers such as TNF-α, IL-6, and IL-17 in peripheral blood. The magnitude of these effects is small and does not warrant comparison with the action of biologic agents, which remain indispensable when indicated.
2. Axial Analgesia via GV and BL Points
GV-4 (Mingmen — "gate of life"), GV-14, and the paravertebral BL points (BL-22 to BL-25) produce segmental analgesia along the entire spine. Stimulation of the lumbosacral paravertebral points recruits Aβ afferent fibers that inhibit the C nociceptors of the sacroiliac joints and inflamed spinous processes via spinal gate control.
3. Reduction of Morning Stiffness
Morning stiffness in AS has an inflammatory component (nighttime vascular congestion + accumulated inflammatory mediators) and a muscular component (protective paravertebral hypertonia). Evening or nighttime acupuncture at GV-4 + BL-23 + BL-40 reduces morning stiffness as assessed on BASDAI-Q5 by acting on both components.
4. Improved Spinal Mobility
ST-36 + SP-6 improve muscle perfusion and paravertebral myofascial elasticity. Relaxation of the iliocostalis and multifidus muscles, which are tense secondary to chronic axial pain, improves mobility on the Schober scale — complementing the role of physical therapy.
Spine Points
- • GV-4 — Mingmen: lumbar spine
- • GV-14 — Dazhui: cervicothoracic spine
- • BL-22 to BL-25 — paravertebral L1–L4
- • BL-27 to BL-30 — sacroiliac, S1–S4
Systemic Points
- • ST-36 — anti-inflammatory, HPA axis
- • SP-6 — systemic, perfusion
- • LI-11 — anti-inflammatory (heat)
- • BL-40 — back and lumbar region
For Enthesitis
- • Needling of active enthesitis: 2–3 mm from the insertion
- • Achilles tendon: BL-60 + KI-3 + BL-61
- • Iliac: BL-27 + GB-30
- • EA 2 Hz on the affected tendon
Scientific Evidence
The Clinical Rheumatology meta-analysis (2021) synthesized 9 RCTs with 786 patients, using outcome scales specific to AS: BASDAI, BASFI, and ASDAS.
RESULTS BY OUTCOME SCALE
| SCALE | CHANGE WITH ACUPUNCTURE | MID (CLINICALLY SIGNIFICANT DIFFERENCE) | INTERPRETATION |
|---|---|---|---|
| BASDAI (0–10) | −1.8 pts | MID = 1.1 pts | Above the MID — clinically significant |
| BASFI (0–10) | −1.6 pts | MID = 1.3 pts | Borderline — significant in some studies |
| ASDAS-CRP (0–5) | −0.7 pts | MID = 1.1 pts (very significant) | Below the MID of major importance — modest |
| VAS pain (0–10) | −3.2 pts | MID = 2.0 pts | Above the MID — clinically relevant |
| CRP (mg/L) | −12 mg/L | — | Documented systemic anti-inflammatory effect |
Clinical Protocol in Ankylosing Spondylitis
Treatment Stages
Initial Assessment
Baseline BASDAI and BASFI, CRP and ESR, current biologic agent (if any), active enthesitis (location). Communication with the responsible rheumatologist. Contraindications: acute uveitis flare (unrelated to the spine), active intercurrent infection.
Intensive Phase (BASDAI >4)
Two sessions/week. Protocol: GV-4 + GV-14 (axial midline), BL-23 to BL-25 bilaterally (lumbar paravertebrals), BL-27 to BL-30 (sacroiliacs), ST-36 + SP-6 (systemic). EA 2 Hz at BL-23 to BL-25. Add LI-11 if CRP is elevated. Active enthesitis: perilesional needling 2–3 mm from the insertion.
Maintenance
One session/week. Reduce to biweekly after sustained BASDAI <2. Monthly maintenance prevents recurrences in patients with AS controlled by biologic therapy. Reassess BASDAI quarterly.
When to See a Medical Acupuncturist for AS
Priority Indications
- • Persistent residual axial pain in a patient on biologic therapy
- • Gastric intolerance to NSAIDs — alternative without gastropathy
- • AS with an active enthesitis component (heel, iliac, sternum)
- • Intense morning stiffness without sufficient response to NSAIDs
- • Mild AS (BASDAI <4) without indication for biologic therapy yet
- • Complement to the physical therapy and exercise program
Relative Contraindications
- • Active infection (biologic + acupuncture → increased risk)
- • Severe neutropenia in immunosuppressed patients
- • Active acute anterior uveitis (treat the eye first)
- • Recent vertebral compression fracture (<6 weeks)
- • Full anticoagulation — adapt paravertebral points
Frequently Asked Questions
Frequently Asked Questions
No. To date, no non-biologic treatment has demonstrated reduction in radiographic progression in AS. Anti-TNF-α and anti-IL-17 agents have evidence of reducing structural progression — especially when started early. Acupuncture has no demonstrated effect of this kind and should not be indicated with that goal. Its role is symptom control: pain, stiffness, and quality of life.
Yes, with strict sanitary precautions. Biologic agents cause significant immunosuppression. It is mandatory to ensure absolute sterility of the needles (single use) and adequate antisepsis. Do not perform acupuncture during episodes of intercurrent infection. Inform the rheumatologist that the patient is on combined treatment. There is no known pharmacologic interaction between acupuncture and any biologic agent for AS.
Morning stiffness tends to respond more quickly than pain. Many patients report improvement in morning stiffness after 3–4 acupuncture sessions. In the comparative RCT with naproxen, morning stiffness (BASDAI-Q5 and Q6) improved by 2.4 points after 4 weeks — a result superior to the NSAID. The evening session (5–7 PM) appears more effective at reducing the morning stiffness of the following day.
The limitation of spinal mobility in advanced AS requires adaptation of positioning. For patients with flattened lordosis or fixed kyphosis, we use a lateral decubitus or semi-seated position instead of the conventional prone decubitus. The medical acupuncturist experienced in rheumatology adapts the protocol and positioning to the specific physical limitations of each patient.